To decipher the impact of inflammasome on HIV-1 pathogenesis in vivo, we treated huNSG mice daily by intraperitoneal injection of the caspase-1 inhibitor VX-765 (Wannamaker et al., 2007) at the dose of 200 mg/kg (Zhang and Zheng, 2016; Ravizza et al., 2008) for 21 consecutive days starting on day 2 after HIV-1 infection to cover the early upregulation of inflammasome-related genes. Here, CASP1 is linked to HIV-1 infection.